Literature DB >> 8098507

Tryptamine: a metabolite of tryptophan implicated in various neuropsychiatric disorders.

D D Mousseau1.   

Abstract

Although early interest in the biomedical relevance of tryptamine has waned in recent years, it is clear from the above discussion that the study of tryptamine is worthy of serious consideration as a factor in neuropsychiatric disorders. The study of [3H]-tryptamine binding sites indicates an adaptive responsiveness characteristic of functional receptors. The question raised by Jones (1982d) on whether tryptamine is acting centrally as a neurotransmitter or a neuromodulator still remains mostly unanswered, although the evidence cited within this review strongly suggests a modulatory role for this neuroactive amine (see also Juorio and Paterson, 1990). The synthesis and degradative pathways of tryptamine, as well as the intricate neurochemical and behavioral consequences of altering these pathways, are now more fully understood. It is not yet clear what the role of tryptamine is under normal physiological [homeostatic] conditions, however, its role during pathological conditions such as mental and physical stress, hepatic dysfunction and other disorders of metabolism (i.e. electrolyte imbalance, increased precursor availability, enzyme induction or alterations in enzyme co-factor availability) may be quite subtle, perhaps accounting for various sequelae hitherto considered idiopathic. The evidence for a primary role for tryptamine in the etiology of mental or neurological diseases is still relatively poor, although the observations that endogenous concentrations of tryptamine are particularly susceptible to pharmacological as well as physiological manipulations serve to reinforce the proposition that this indoleamine is not simply a metabolic accident but rather a neuroactive compound in its own right. Finally, one might wonder what proportion of the data attributed to modifications of 5-HT metabolism might, in fact, involve unrecognized changes in the concentrations of other neuroactive metabolites of tryptophan such as tryptamine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8098507     DOI: 10.1007/bf01000528

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  227 in total

1.  Tryptamine and 5-hydroxytryptamine-induced hypothermia in mice.

Authors:  D J Dooley; R M Quock
Journal:  J Pharm Pharmacol       Date:  1976-10       Impact factor: 3.765

Review 2.  Tryptamine may couple dopaminergic and serotonergic transmission in the brain.

Authors:  A V Juorio; I A Paterson
Journal:  Gen Pharmacol       Date:  1990

3.  The effects of some indolalkylamines on the uptake and release of 5-hydroxytryptamine in rat striatum [proceedings].

Authors:  G B Baker; I L Martin; P R Mtichel
Journal:  Br J Pharmacol       Date:  1977-09       Impact factor: 8.739

4.  Serotonin metabolism in rat brain after surgical diversion of the portal venous circulation.

Authors:  R J Baldessarini; J E Fischer
Journal:  Nat New Biol       Date:  1973-09-05

5.  Evaluation of the uptake of various amines into storage vesicles of intact human platelets.

Authors:  J L Costa; D L Murphy; J Reveille
Journal:  Br J Pharmacol       Date:  1977-10       Impact factor: 8.739

6.  The activation of serotonin receptors by tryptamine induces hyperinsulinemia in mice.

Authors:  J Yamada; Y Sugimoto; I Kimura; N Takeuchi; K Horisaka
Journal:  Eur J Pharmacol       Date:  1990-06-08       Impact factor: 4.432

7.  Comparison of serotoninergic to muscarinic cholinergic stimulation of phosphoinositide-specific phospholipase C in rat brain cortical membranes.

Authors:  M A Wallace; E Claro
Journal:  J Pharmacol Exp Ther       Date:  1990-12       Impact factor: 4.030

8.  Characterization of [3H]tryptamine binding sites in brain.

Authors:  C S Cascio; K J Kellar
Journal:  Eur J Pharmacol       Date:  1983-11-11       Impact factor: 4.432

9.  The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat.

Authors:  M D Tricklebank; C Forler; J R Fozard
Journal:  Eur J Pharmacol       Date:  1984-11-13       Impact factor: 4.432

10.  Synergistic behavioral effects of serotonin and tryptamine injected intrathecally in mice.

Authors:  A A Larson; G L Wilcox
Journal:  Neuropharmacology       Date:  1984-12       Impact factor: 5.250

View more
  9 in total

1.  Tryptamine induces tryptophanyl-tRNA synthetase-mediated neurodegeneration with neurofibrillary tangles in human cell and mouse models.

Authors:  Elena L Paley; Galina Denisova; Olga Sokolova; Natalia Posternak; Xukui Wang; Anna-Liisa Brownell
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

Review 2.  The biochemistry of Tourette's syndrome.

Authors:  P R Chokka; G B Baker; R A Bornstein; C M de Groot
Journal:  Metab Brain Dis       Date:  1995-06       Impact factor: 3.584

Review 3.  Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds.

Authors:  Guillermo Gervasini; Juan Antonio Carrillo; Julio Benitez
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 4.  Genetic and biochemical changes of the serotonergic system in migraine pathobiology.

Authors:  Claudia Francesca Gasparini; Robert Anthony Smith; Lyn Robyn Griffiths
Journal:  J Headache Pain       Date:  2017-02-13       Impact factor: 7.277

5.  Pre-clinical Pharmacokinetic and Metabolomic Analyses of Isorhapontigenin, a Dietary Resveratrol Derivative.

Authors:  Yu Dai; Samuel C M Yeo; Peter J Barnes; Louise E Donnelly; Lai C Loo; Hai-Shu Lin
Journal:  Front Pharmacol       Date:  2018-07-11       Impact factor: 5.810

6.  Developing E. coli-E. coli co-cultures to overcome barriers of heterologous tryptamine biosynthesis.

Authors:  Xiaonan Wang; Lizelle Policarpio; Dhara Prajapati; Zhenghong Li; Haoran Zhang
Journal:  Metab Eng Commun       Date:  2019-11-21

7.  Towards an Integrative Understanding of tRNA Aminoacylation-Diet-Host-Gut Microbiome Interactions in Neurodegeneration.

Authors:  Elena L Paley; George Perry
Journal:  Nutrients       Date:  2018-03-26       Impact factor: 5.717

8.  Tryptamine Attenuates Experimental Multiple Sclerosis Through Activation of Aryl Hydrocarbon Receptor.

Authors:  Nicholas Dopkins; William Becker; Kathryn Miranda; Mike Walla; Prakash Nagarkatti; Mitzi Nagarkatti
Journal:  Front Pharmacol       Date:  2021-01-25       Impact factor: 5.810

Review 9.  Gut Microbiota Metabolites in Major Depressive Disorder-Deep Insights into Their Pathophysiological Role and Potential Translational Applications.

Authors:  Miguel A Ortega; Miguel Angel Alvarez-Mon; Cielo García-Montero; Oscar Fraile-Martinez; Luis G Guijarro; Guillermo Lahera; Jorge Monserrat; Paula Valls; Fernando Mora; Roberto Rodríguez-Jiménez; Javier Quintero; Melchor Álvarez-Mon
Journal:  Metabolites       Date:  2022-01-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.